43.20
-1.75 (-3.89%)
| Penutupan Terdahulu | 44.95 |
| Buka | 44.66 |
| Jumlah Dagangan | 452,062 |
| Purata Dagangan (3B) | 508,980 |
| Modal Pasaran | 1,208,433,536 |
| Harga / Jualan (P/S) | 9.95 |
| Harga / Buku (P/B) | 114.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -125.70% |
| Margin Operasi (TTM) | -99.16% |
| EPS Cair (TTM) | -4.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 286.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,016.89% |
| Nisbah Semasa (MRQ) | 8.25 |
| Aliran Tunai Operasi (OCF TTM) | -108.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.04 M |
| Pulangan Atas Aset (ROA TTM) | -15.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -343.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | AnaptysBio, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.63 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.09% |
| % Dimiliki oleh Institusi | 133.99% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 85.00 (Stifel, 96.76%) | Beli |
| Median | 72.50 (67.82%) | |
| Rendah | 50.00 (Truist Securities, 15.74%) | Pegang |
| Purata | 70.83 (63.96%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 55.74 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 12 Mar 2026 | 75.00 (73.61%) | Beli | 55.41 |
| Truist Securities | 09 Mar 2026 | 50.00 (15.74%) | Pegang | 55.41 |
| Stifel | 05 Mar 2026 | 85.00 (96.76%) | Beli | 57.28 |
| Barclays | 04 Mar 2026 | 79.00 (82.87%) | Beli | 60.55 |
| 20 Jan 2026 | 78.00 (80.56%) | Beli | 46.21 | |
| HC Wainwright & Co. | 04 Mar 2026 | 66.00 (52.78%) | Beli | 60.55 |
| UBS | 07 Jan 2026 | 70.00 (62.04%) | Beli | 45.21 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Anaptys Announces Participation at Upcoming Investor Conferences |
| 08 Jan 2026 | Pengumuman | Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary |
| 06 Jan 2026 | Pengumuman | Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 15 Dec 2025 | Pengumuman | Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |